Home   >   CSC-OpenAccess Library   >    Manuscript Information
Full Text Available

This is an Open Access publication published under CSC-OpenAccess Policy.
Publications from CSC-OpenAccess Library are being accessed from over 74 countries worldwide.
Data Mining Visualization To Support Biochemical Markers for Liver Fibrosis In Patients with Chronic Hepatitis C Cirus
Ayman Khedr , Samir Sabry
Pages - 107 - 116     |    Revised - 01-07-2011     |    Published - 05-08-2011
Volume - 2   Issue - 3    |    Publication Date - July / August 2011  Table of Contents
Data Mining, Visualization, Hepatitis C, Serum Markers, Liver Fibrosis
The reference diagnostic test to detect fibrosis is liver biopsy (LB), a procedure subject to various limitations, including risk of patient injury and sampling error. FibroTest (FT) and ActiTest (AT) are biochemical markers (noninvasive tests) used in determining the level of fibrosis and the degree of necroinflammatory activity in the liver. The objective of this work is to discover the differences in the temporal patterns between noninvasive tests and liver biopsy by visualization tools, which made it easier to understand the relations of the complicated rules. This Study ware focused on the major serum fibrosis markers (FT/AT). The test uses a combination of serum biochemical markers with visualization technique to evaluate whether biochemical markers can be used to estimate the stage of liver fibrosis and necro-inflammatory activity in the liver.
1 Google Scholar 
2 CiteSeerX 
3 refSeek 
4 Scribd 
5 SlideShare 
6 PdfSR 
1 Imbert- Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. “Biochemical markers of liver fibrosis in patients with hepatitis C virus infection : a prospective study”.Lancet, 2001, 357, 9262, 1069-1075.
2 Lavrak N, “Selected techniques for data mining in medicine", Artificial Intelligence in Medicine, 16, 2{23, 125{134, 1999
3 Nguyen, D.D., Ho, T.B., Kawasaki, S., “Knowledge visualization in Hepatitis Study", Asia Pacic Symposium on Information Visualization APVIS'06, 59{62, 2006
4 Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, et al. “Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C”. Hepatology 2008; 47(3):789-798.
5 White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, Skehel M, et al. “Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection” J Transl Med 2007; 5:33.
6 McGill DB, Rakela J, Zinsmeister AR, Ott BJ. “A 21-year experience with major hemorrhage after percutaneous liver biopsy”.Gastroenterology 1990; 99: 1396-1400.
7 Van Thiel DH, Gavaler JS, Wright H, Tzakis A. “Liver biopsy.Its safety and complications as seen at a liver transplant center”. Transplantation 1993; 55: 1087-1090
8 Stauber RE, Lackner C. “Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C”.World J Gastroenterol 2007 August 28; 13(32): 4287-4294
9 Shahzad Ashraf. “Noninvasive evaluation of liver fibrosis in patients with chronic hepatitis B and C“.PhD Thesis, Baqai Medical University, 2006
10 The Fibrotest-Actitest-HCV FIBROSURE Available from: URL:http://www.biopredictive.com/intl/physician/fibrotest-for-hcv/view?set_language=en
11 Accessed February 4, 2011.Available at URL address:https://www.labcorp.com/pdf/08_HCV_Fibrosure_TR_1080.pdf
12 Knodell RG, Ishak KG, Black WC, et al. “Formulation and application 3of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis”.Hepatology 1981;1(5):431-5
13 Bedossa P, Poynard T. “An algorithm for the grading of activity 4. In chronic hepatitis C. the METAVIR cooperative study group”. Hepatology 1996; 24(2):289-93.
14 T. Soukup and I. Davidson “Visual Data Mining: Techniques and Tools for Data Visualization and Mining”, John Willey & Sons Inc, pp.5-7 (2002)
15 Vitaly Friedman (2008) "Data Visualization and Infographics" in: Graphics, Monday Inspiration, January 14th, 2008
16 FI-BROCHURE: The Fibrotest-Actitest-HCV FIBROSURE Investigator's Brochure. Available from: URL: http://www. biopredictive.com
17 Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of Chronic hepatitis C: A systematic review. Hepatology 2002; 36:S161-72.
18 Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.Hepatology 2003; 38:481-92.
19 Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al.Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-55.
20 Munteanu M, Messous D, Thabut D, Imbert-Bismut F, Jouys M, Massard J, et al. Intraindividual fasting versus postprandial variation of biochemical markers of liver fibrosis(Fibrotest) and activity (Actitest). Comp Hepatol 2004; 3:3.
21 Bertin, J. 1983. Semiology of Graphics, University of Wisconsin Press.
Associate Professor Ayman Khedr
- Egypt
Mr. Samir Sabry
- Egypt